Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors-Reference-Cited by-同舟云学术

Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors

Published:2023-02 Issue:1 Volume:21 Page:69-75
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Chawla Neal S.^ORCID,Sayegh Nicolas^ORCID,Tripathi Nishita^ORCID,Govindarajan Ameish,Zengin Zeynep B.,Phillip Errol J.,Dizman Nazli^ORCID,Meza Luis^ORCID,Muddasani Ramya,Chehrazi-Raffle Alexander^ORCID,Malhotra Jasnoor,Hsu JoAnn,Agarwal Neeraj,Pal Sumanta K.,Tripathi Abhishek

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference34 articles.

1. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Engl J Med,2017

2. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial;Sharma;Lancet Oncol,2017

3. avelumab maintenance therapy for advanced or metastatic urothelial carcinoma;Powles;N Engl J Med,2020

4. New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab;Pond;J Clin Oncol,2018

5. A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma;Nassar;Br J Cancer,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis;International Journal of Surgery;2024-04-03

2. Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study;Anticancer Research;2024-03-27

3. Effect of the TERT mutation on the prognosis of patients with urothelial carcinoma: a systematic review and meta-analysis;BMC Urology;2023-11-02

4. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment;Journal for ImmunoTherapy of Cancer;2023-09

5. Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer;Frontiers in Oncology;2023-04-05